Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1-18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m2. Using a single-stage design, with an overall response rate (ORR) ≤ 30% defined as not promissing and ORR > 55% as expected, 25 patients needed to be recruited to achieve 80% power at 0.05 significance level. Thirty-two patients were enrolled, 28 were treated, 27 were evaluable for response. The estimated ORR was 81.5% (95%CI: 61.9-93.7%), and 81.8% (18/22) of the responding subjects were minimal residual disease (MRD) negative. The study met its primary endpoint. Median follow up of survivors was 16 months (IQR: 14.49-20.07). One year Event Free Survival was 36.7% (95% CI: 22.2-60.4%), and Overall Survival was 55.1% (95% CI: 39.1-77.7%). Eighteen patients received consolidation (with HSCT and/or CAR T-cells therapy). Sinusoidal obstructive syndrome (SOS) occurred in seven patients. MRD negativity seemed correlated to calicheamicin sensitivity in vitro, but not to CD22 surface expression, saturation, or internalization. InO was effective in this population. The most relevant risk was the occurrence of SOS, particularly when InO treatment was followed by HSCT.

Department of Clinical Genetics Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands

Department of Hematology Oncology and of Cell and Gene Therapy IRCCS Ospedale Pediatrico Bambino Gesú Sapienza University of Rome Rome Italy

Department of Immunology Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands

Department of pediatric Hematology and Oncology Hopital Armand Trousseau APHP Sorbonne Université Paris France

Department of Pediatric Hematology and Oncology University Hospital Motol Prague Czech Republic

Department of Pediatric Oncology and Hematology Hospital Niño Jesús Madrid Spain

Department of Pediatric Oncology Erasmus MC Sophia Children's Hospital Rotterdam the Netherlands

Department of Pediatric Oncology Essen University Hospital Essen Germany

Department of Pediatrics Division of Oncology and Hematology Charité Universitätsmedizin Berlin Berlin Germany

Department of Pediatrics Rostock University Medical Centre Rostock Germany

Division of Pediatric Hematology and Oncology Sheba Medical Center Ramat Gan Israel

Institut de Recerca Sant Joan de Déu Barcelona Spain

Institute of Pediatric Hematology and Oncology Civil Hospital of Lyon Claude Bernard University Lyon France

IntReALL study group Berlin Germany

Oncode Institute Utrecht the Netherlands

Pediatric Hematology and Oncology University Children's Hospital Muenster Münster Germany

Pediatric Hematology Hôpital Jeanne de Flandre CHRU de Lille Lille France

Pediatric Hematology Oncology Unit Department of Pediatrics MBBM Foundation ASST Monza University of Milano Bicocca Monza Italy

Pediatric Oncology and Hematology Department Hospital Sant Joan de Déu de Barcelona Barcelona Spain

Pfizer Inc Groton CT USA

Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

Service d'Hématologie Immunologie Oncologie Hôpital des Enfants CHU Toulouse Toulouse France

Service Onco Hématologie Pédiatrique Hôpital Mère Enfant Nantes University Hospital Nantes France

St Anna Children's Hospital Medical University of Vienna Vienna Austria

000      

00000naa a2200000 a 4500

001      

bmc22018226

003      

CZ-PrNML

005      

20220804134634.0

007      

ta

008      

220720s2022 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1038/s41375-022-01576-3 $2 doi

035    __

$a (PubMed)35468945

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Pennesi, Edoardo $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands

245    10

$a Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial / $c E. Pennesi, N. Michels, E. Brivio, VHJ. van der Velden, Y. Jiang, A. Thano, AJC. Ammerlaan, JM. Boer, HB. Beverloo, B. Sleight, Y. Chen, B. Vormoor-Bürger, S. Rives, B. Bielorai, C. Rössig, A. Petit, C. Rizzari, G. Engstler, J. Starý, FJ. Bautista Sirvent, C. Chen-Santel, B. Bruno, Y. Bertrand, F. Rialland, G. Plat, D. Reinhardt, L. Vinti, A. Von Stackelberg, F. Locatelli, CM. Zwaan

520    9_

$a Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1-18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m2. Using a single-stage design, with an overall response rate (ORR) ≤ 30% defined as not promissing and ORR > 55% as expected, 25 patients needed to be recruited to achieve 80% power at 0.05 significance level. Thirty-two patients were enrolled, 28 were treated, 27 were evaluable for response. The estimated ORR was 81.5% (95%CI: 61.9-93.7%), and 81.8% (18/22) of the responding subjects were minimal residual disease (MRD) negative. The study met its primary endpoint. Median follow up of survivors was 16 months (IQR: 14.49-20.07). One year Event Free Survival was 36.7% (95% CI: 22.2-60.4%), and Overall Survival was 55.1% (95% CI: 39.1-77.7%). Eighteen patients received consolidation (with HSCT and/or CAR T-cells therapy). Sinusoidal obstructive syndrome (SOS) occurred in seven patients. MRD negativity seemed correlated to calicheamicin sensitivity in vitro, but not to CD22 surface expression, saturation, or internalization. InO was effective in this population. The most relevant risk was the occurrence of SOS, particularly when InO treatment was followed by HSCT.

650    _2

$a akutní nemoc $7 D000208

650    _2

$a mladiství $7 D000293

650    12

$a kalicheamiciny $7 D000080084

650    _2

$a dítě $7 D002648

650    _2

$a předškolní dítě $7 D002675

650    _2

$a lidé $7 D006801

650    _2

$a kojenec $7 D007223

650    _2

$a inotuzumab ozogamicin $7 D000080045

650    12

$a akutní lymfatická leukemie $x farmakoterapie $7 D054198

650    _2

$a doba přežití bez progrese choroby $7 D000077982

655    _2

$a klinické zkoušky, fáze II $7 D017427

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Michels, Naomi $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands $u Oncode Institute, Utrecht, the Netherlands

700    1_

$a Brivio, Erica $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands

700    1_

$a van der Velden, Vincent H J $u Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands $1 https://orcid.org/0000000194573763

700    1_

$a Jiang, Yilin $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands

700    1_

$a Thano, Adriana $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands

700    1_

$a Ammerlaan, Anneke J C $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands

700    1_

$a Boer, Judith M $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Oncode Institute, Utrecht, the Netherlands $1 https://orcid.org/0000000348487789

700    1_

$a Beverloo, H Berna $u Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

700    1_

$a Sleight, Barbara $u Pfizer Inc, Groton, CT, USA

700    1_

$a Chen, Ying $u Pfizer Inc, Groton, CT, USA

700    1_

$a Vormoor-Bürger, Britta $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands

700    1_

$a Rives, Susana $u Pediatric Oncology and Hematology Department, Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain $u Institut de Recerca Sant Joan de Déu, Barcelona, Spain $1 https://orcid.org/0000000256581831

700    1_

$a Bielorai, Bella $u Division of Pediatric Hematology and Oncology, Sheba Medical Center, Ramat-Gan, Israel

700    1_

$a Rössig, Claudia $u Pediatric Hematology and Oncology, University Children's Hospital Muenster, Münster, Germany

700    1_

$a Petit, Arnaud $u Department of pediatric Hematology and Oncology, Hopital Armand Trousseau, APHP, Sorbonne Université, Paris, France $1 https://orcid.org/0000000183631622

700    1_

$a Rizzari, Carmelo $u Pediatric Hematology-Oncology Unit, Department of Pediatrics, MBBM Foundation, ASST Monza, University of Milano-Bicocca, Monza, Italy

700    1_

$a Engstler, Gernot $u St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria

700    1_

$a Starý, Jan $u Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic

700    1_

$a Bautista Sirvent, Francisco J $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Department of Pediatric Oncology and Hematology, Hospital Niño Jesús, Madrid, Spain

700    1_

$a Chen-Santel, Christiane $u Department of Pediatrics, Division of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany $u Department of Pediatrics, Rostock University Medical Centre, Rostock, Germany

700    1_

$a Bruno, Benedicte $u Pediatric Hematology, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France

700    1_

$a Bertrand, Yves $u Institute of Pediatric Hematology and Oncology, Civil Hospital of Lyon, Claude Bernard University, Lyon, France

700    1_

$a Rialland, Fanny $u Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France

700    1_

$a Plat, Geneviève $u Service d'Hématologie-Immunologie-Oncologie, Hôpital des Enfants, CHU Toulouse, Toulouse, France

700    1_

$a Reinhardt, Dirk $u Department of Pediatric Oncology, Essen University Hospital, Essen, Germany

700    1_

$a Vinti, Luciana $u Department of Hematology, Oncology and of Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesú, Sapienza, University of Rome, Rome, Italy

700    1_

$a Von Stackelberg, Arend $u Department of Pediatrics, Division of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany $u IntReALL study group, Berlin, Germany

700    1_

$a Locatelli, Franco $u Department of Hematology, Oncology and of Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesú, Sapienza, University of Rome, Rome, Italy

700    1_

$a Zwaan, Christian M $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. c.m.zwaan@prinsesmaximacentrum.nl $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. c.m.zwaan@prinsesmaximacentrum.nl $1 https://orcid.org/0000000168928268

773    0_

$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 36, č. 6 (2022), s. 1516-1524

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35468945 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220720 $b ABA008

991    __

$a 20220804134628 $b ABA008

999    __

$a ok $b bmc $g 1822025 $s 1169469

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 36 $c 6 $d 1516-1524 $e 20220425 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138

LZP    __

$a Pubmed-20220720